Overview

* Catalyst Q2 2025 revenue rises 19.4% yr/yr, beating analyst expectations, per LSEG data

* Adjusted EPS for Q2 exceeds estimates, reflecting strong operational performance

* AGAMREE Q2 net product revenue up 212.9% yr/yr, FYCOMPA declines due to generic entry

Outlook

* Catalyst reaffirms 2025 revenue guidance of $545 mln to $565 mln

* Company expects broad-based growth and sustained demand in 2025

* Catalyst anticipates impact from generic competition on FYCOMPA

* Company highlights strong cash position to support strategic initiatives

Result Drivers

* FIRDAPSE DEMAND - Despite temporary insurance processing impact, FIRDAPSE net revenue grew 9.7% YoY, reflecting strong demand

* AGAMREE ADOPTION - AGAMREE revenue surged 212.9% YoY, driven by accelerating physician adoption post-launch

* FYCOMPA GENERIC IMPACT - FYCOMPA revenue decreased 6.0% YoY due to generic competition following loss of exclusivity

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $146.60 $140.60

Revenue mln mln (8

Analysts

)

Q2 Beat $0.68 $0.39 (5

Adjusted Analysts

EPS )

Q2 $86.40

Adjusted mln

Net

Income

Q2 Net $52.10

Income mln

Q2 $66.30

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy."

* Wall Street's median 12-month price target for Catalyst Pharmaceuticals Inc ( CPRX ) is $33.00, about 32.7% above its August 5 closing price of $22.22

* The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 16 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)